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Abstract
BACKGROUND: Squamous cell carcinoma (SCC) is the most common type of cervical cancer. Pelvic lymph node 
metastasis in cervical SCC is common. Programmed death ligand 1 (PD-L1) on tumor cells has been reported to 
impede anti-tumor immunity, resulting in immune evasion. C-X-C chemokine receptor type 4 (CXCR4) plays an 
important role in proliferation, survival, and migration (chemotaxis) of tumor cells.
AIM: This study aimed to analyze the association of PD-L1 and CXCR4 immunoexpression with pelvic lymph node 
metastasis in cervical SCC.
MATERIALS AND METHODS: Forty cases of cervical SCC in the Department of Anatomical Pathology, Faculty 
of Medicine, Padjadjaran University, Dr. Hasan Sadikin Hospital, Bandung, during 2013–2018 were collected and 
divided into two groups; (1) cervical SCC metastasize to pelvic lymph node and (2) cervical SCC non-metastasize 
to pelvic lymph node, of 20 cases, respectively. The expression of PD-L1 and CXCR4 was detected using 
immunohistochemistry.
RESULTS: High immunoexpression of PD-L1 and CXCR4 in cervical SCC showed significant association with pelvic 
lymph node metastasis (p < 0.05). The stepwise logistic regression analysis revealed that both PD-L1 and CXCR4 
immunoexpression influenced pelvic lymph node metastasis simultaneously.
CONCLUSION: It could be concluded that the higher PD-L1 and CXCR4 immunoexpression showed the higher 
ability of tumor cells to metastasize to the pelvic lymph node.
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Introduction
Cervical cancer is one of the most common forms 
of cancer in women and a leading cause of death among 
gynecological malignancies worldwide. In Indonesia, 
cervical cancer is the second most common women 
cancer in terms of incidence and mortality [1]. Squamous 
cell carcinoma is the most common type of cervical 
cancer [2], [3]. Squamous cell carcinoma is defined as 
an invasive epithelial tumor composed of squamous cells 
of varying degrees of differentiation [2]. Squamous cell 
carcinoma is an aggressive cancer and pelvic lymph node 
metastasis in cervical SCC is common [4].
Pelvic lymph node metastasis (based on 
imaging or pathological findings, where available) is one 
of the parameters to assign the stage based on new 2018 
International Federation of Gynecology and Obstetrics 
(FIGO) staging system for cervical cancer [5], [6]. PD-L1 
and CXCR4 immunohistochemistry on cervical SCC 
are expected to be an alternative method to predict 
pelvic lymph node metastasis in cervical SCC.
PD-L1, also known as B7 homolog 1 (B7-H1) 
or cluster of differentiation (CD) 274, is a ligand of 
programmed death protein 1 (PD-1), encoded by 
the CD274 gene, which is located in chromosome 
9p24.1 [7], [8], [9], [10], [11], [12]. It is expressed in different 
tissues, but mainly in activated T and B cells, dendritic cells, 
monocytes, and various types of tumor cells [10], [13]. The 
PD-1/PD-L1 interaction (axis) inhibits T-cells activation 
and increases inhibitory cytokines secretion, results 
in immune evasion [14], [15], [16], [17], [18]. PD-L1 
overexpression in tumor cells is an indicator of tumor 
progression [19], [20].
CXCR4, also known as fusin or CD184, is a 
specific receptor for the CXC chemokine stromal cell-
derived factor-1α (SDF-1α, also known as C-X-C motif 
chemokine ligand 12 [CXCL12]). CXCR4 is a G-protein-
coupled chemokine receptor encoded on chromosome 
2 [21], [22], [23], [24]. Similar to CXCL12, the expression 
of CXCR4 is low or absent in many healthy tissues, but 
it is demonstrated that CXCR4 is highly expressed in 
various different tumor types [23], [25]. The CXCR4/
CXCL12 axis in cancer is associated with chemotaxis, 
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migration, proliferation, and cell tumor survival, also 
being an indicator of higher tumor progression [24], [26].
The association of PD-L1 immunoexpression 
with pelvic lymph node metastasis in cervical SCC has 
been investigated in various studies. However, the 
results are still conflicting [27], [28], [15]. The same 
association conflict also seen in various studies of 
CXCR4 immunoexpression with pelvic lymph node 
metastasis in cervical SCC [29], [30], [31].
Therefore, this study aimed to analyze the 
association of PD-L1 and CXCR4 immunoexpression 
with pelvic lymph node metastasis in cervical SCC.
Materials and Methods
This was an observational analytic study with 
a cross-sectional design. The research has received 
ethical approval from the Ethical Committee of 
Universitas Padjadjaran with certificate number 1214/
UN6.KEP/EC/2019.
Samples selection
The samples were paraffin blocks from cervical 
cancer patients who underwent radical hysterectomy 
and pelvic lymphadenectomy, had been diagnosed 
histopathologically as cervical SCC in the Department of 
Anatomical Pathology, Faculty of Medicine, Padjadjaran 
University, Dr. Hasan Sadikin Hospital, Bandung, 
during the period of 2013–2018. Samples were divided 
into two groups: (1) Cervical SCC metastasize to pelvic 
lymph node and (2) cervical SCC non-metastasize to 
pelvic lymph node, of 20 cases, respectively.
Inclusion criteria include: (1) Cases of cervical 
cancer that had undergone radical hysterectomy 
and lymphadenectomy, had been diagnosed 
histopathologically as cervical SCC (cervical SCC 
metastasize to pelvic lymph node and cervical SCC non-
metastasize to pelvic lymph node); (2) paraffin block was 
available; (3) patients have not received radiotherapy 
or chemotherapy for the treatment of cervical SCC; and 
(4) patient clinical data were available.
Exclusion criteria include: (1) The paraffin 
block of tumor mass was empty, damaged, or paraffin 
ribbons cannot be stained with PD-L1 and CXCR4 
immunohistochemistry and (2) cases of cervical SCC 
non-metastasize to pelvic lymph node with <10 lymph 
nodes removed.
Data extraction
Characteristic data, including age, stage, 
histopathological subtype, histopathological grade, 
tumor size, and status of pelvic lymph node metastasis 
were extracted from pathological, cancer registry 
reports, and medical record databases.
Immunohistochemistry staining and 
scoring
PD-L1 and CXCR4 immunohistochemistry 
were performed on the whole samples. Each paraffin 
block was sectioned at 4 μm and deparaffinized using 
xylene. After rehydration and washing, the sections 
were incubated by ethylenediaminetetraacetic acid 
(EDTA) buffer pH 6.0 for antigen retrieval. After 
blocking, the specimens were incubated for 1 h using 
primary antibodies rabbit monoclonal anti-PD-L1 (clone 
28-8, cat No. ab205921, Abcam, Inc., Cambridge, USA; 
1:200 dilution) and rabbit polyclonal anti-CXCR4 (cat 
No. GTX13854, GeneTex, Inc., California, USA; 1:300 
dilution). The samples were labeled using labeled 
streptavidin-biotin immunoperoxidase complex by 
One Step Neopoly Detection Kit (Biogear Scientific, 
BioVentures, Inc., Iowa, USA), visualized using 
3,3’-diaminobenzidine (DAB), and counterstained using 
Harris hematoxylin. After dehydration, the samples 
were mounted and analyzed. The positive control for 
each marker was normal tonsil tissue (according to 
Abcam and GeneTex recommendation).
The evaluation of immunoexpression from both 
biomarkers was analyzed using histoscore, a combined 
scoring system which is the analysis of intensity and 
staining distribution. Positive result was shown by 
brown color in different areas of the tumor cells for each 
biomarker. PD-L1 positivity was in the cell membrane 
(with or without cytoplasm) of tumor cell; meanwhile, 
CXCR4 was positive if cell membrane and/or cytoplasm 
of tumor cell was also colored brown. The staining 
intensity was scored as 0 (negative), +1 (weak), +2 
(moderate), or 3+ (strong). Positivity of PD-L1 in the 
tumor cell was scored as 0 (<5%) or 1 (≥5%), meanwhile, 
positivity of CXCR4 was scored as 0 (<5%), 1 (5–10%), 
2 (11–50%), 3 (51–75%), or 4 (>75%). Histoscore was 
determined from the multiplication of intensity and 
staining distribution scoring, which was 0–3 for PD-L1 
and 0–12 for CXCR4. The immunoexpression histoscore 
was later categorized as low (≤1 for PD-L1 and ≤6 for 
CXCR4) and high (>1 for PD-L1 and >6 for CXCR4). 
These analyses were performed independently by two 
experienced pathologists who had no prior knowledge 
of characteristic data. The few different scoring from 
both pathologists was resolved by consensus using a 
conference microscope.
Statistical analysis
Statistical analysis using regression logistic 
test. The significance of the data was obtained when p < 
0.05. Data processing using the Statistical Package for 
the Social Sciences (SPSS) version 24.0 for Windows.
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Results
Patients characteristic
Forty patients between 32 and 66 years old were 
included in this study, with mean and median 43.375 and 
44 years old, respectively. Patients ≤45 years old were 
more common than >45 years old. Stage IB1 was the 
most encountered stadium, which was 16 cases (40%). 
The majority histopathological subtypes were non-
keratinized, with 27 cases (67.5%). The most common 
histological grade were moderately differentiated, in 24 
cases (60%). Tumor size <4 cm was the most common 
tumor size, which was 23 cases or 57.5% (Table 1).
Table 1: Patients characteristic
Variable n (%)
Age (year)
Mean ± Std 45.375 ± 9.086
Median 44
Range (min–max)
≤45
>45
32–66
25 (62.5)
15 (37.5)
Stagea
IB1
IB2
IIA1
IIA2
IIB
Histopathological subtype
Non-keratinized
Keratinized
Basaloid
Histopathological grade
Well differentiated
Moderately differentiated
Poorly differentiated
Tumor size
<4 cm
≥4 cm
16 (40)
8 (20)
10 (25)
5 (12.5)
1 (2.5)
27 (67.5)
9 (22.5)
4 (10)
3 (7.5)
24 (60)
13 (32.5)
23 (57.5)
17 (42.5)
aAccording to 2009, FIGO cervical cancer staging system
The association between patients 
characteristic and pelvic lymph node metastasis in 
cervical squamous cell carcinoma is shown in Table 2. 
There was no significant association between patients 
characteristic (age, stage, histopathological subtype, 
histopathological grade, or tumor size) and pelvic lymph 
node metastasis (Table 2).
PD-L1 and CXCR4 immunoexpression
Immunohistochemistry staining on PD-L1 
and CXCR4 was performed on each sample. The 
staining results were evaluated according to intensity 
and staining distribution of positive tumor cells 
(Figures 1 and 2). There were no negative CXCR4 
immunoexpression findings in this study.
Association of PD-L1 immunoexpression 
with pelvic lymph node metastasis in cervical 
squamous cell carcinoma
p value in PD-L1 immunoexpression variable 
was less than 0.05 (p = 0.006), showed a statistically 
significant difference between PD-L1 immunoexpression 
variable in cervical SCC metastasize to pelvic lymph 
Table 2: Association between patients characteristic and 
pelvic lymph node metastasis in cervical squamous cell 
carcinoma
Variable Cervical squamous cell carcinoma group OR p valuea
Metastasize to 
pelvic lymph node
Non-metastasize to 
pelvic lymph node
n (%) n (%)
Age (years)
≤45 14 (56) 11 (44) Ref
>45 6 (40) 9 (60) 0.524 0.330
Stageb
IB1 6 (37,5) 10 (62,5) Ref
IB2 5 (62,5) 3 (37,5) 2.778 0.253
IIA1 5 (50) 5 (50) 1.667 0.532
IIA2 3 (60) 2 (40) 2.550 0.382
IIB 1 (100) 0 (0) NA
Histopathological subtype
Non-keratinized
Keratinized
Basaloid
Histopathological grade
Well differentiated
Moderately differentiated
Poorly differentiated
Tumor size
<4 cm
≥4 cm
14 (51,9)
3 (33,3)
3 (75)
1 (33,3)
12 (50)
7 (53,8)
9 (39,1)
11(64,7)
13 (48,1)
6 (66,7)
1 (25)
2 (66,7)
12 (50)
6 (46,2)
14 (60,9)
6 (35,3)
 
Ref
0.464
2.786
Ref
2.000
2.333
Ref
2.852
0.341
0.400
0.591
0.529
0.114
OR: Odds ratio, Ref: Reference, NA: Not applicable. aSimple regression logistic test, bAccording to 2009, 
FIGO cervical cancer staging system
node group and cervical SCC non-metastasize to pelvic 
lymph node group. Based on odds ratio, it could be 
concluded that the risk of cervical SCC patients with high 
PD-L1 immunoexpression for sustaining pelvic lymph 
node metastasis was 8.5 times higher than cervical 
SCC patients with low PD-L1 immunoexpression 
(confidence interval of 1.861–38.817) (Table 3).
Figure 1: PD-L1 immunoexpression. (a) Strong (+3); (b) moderate 
(+2); (c) weak (+1); (d) negative (0) (200)
a
c d
c
Association of CXCR4 Immunoexpression 
with Pelvic Lymph Node Metastasis in Cervical 
Squamous Cell Carcinoma
p value in CXCR4 immunoexpression variable 
was less than 0.05 (p = 0.001), showed a statistically 
statistically significant difference between CXCR4 
Figure 2: CXCR4 immunoexpression. (a) Strong (+3); (b) moderate 
(+2); (c) weak (+1). (200)
a b c
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Table 3: Association of PD-L1 immunoexpression with pelvic 
lymph node metastasis in cervical squamous cell carcinoma
Variable Cervical squamous cell carcinoma group OR (CI 95%) p valuea
Metastasize to pelvic 
lymph node  n (%)
Non-metastasize to 
pelvic lymph node  n (%)
PD-L1
Low 3 (20) 12 (80) Ref 0.006*
High 17 (68) 8 (32) 8.5 (1.861–38.817)
OR: Odds ratio, CI: Confidence interval, Ref: Reference. aSimple regression logistic test. *p < 0.05, means 
significant or statistically significant
immunoexpression variable in cervical SCC metastasize 
to pelvic lymph node group and cervical SCC non-
metastasize to pelvic lymph node group. Based on 
odds ratio, it could be concluded that the risk of cervical 
SCC patients with high CXCR4 immunoexpression for 
sustaining pelvic lymph node metastasis was 12 times 
higher than cervical SCC patients with low CXCR4 
immunoexpression (confidence interval of 2.7–53.33) 
(Table 4).
Table 4: Association of CXCR4 immunoexpression with pelvic 
lymph node metastasis in cervical squamous cell carcinoma
Variable Cervical squamous cell carcinoma group OR (CI 95%) p valuea
Metastasize to pelvic 
lymph node  n (%)
Non-metastasize to 
pelvic lymph node n (%)
CXCR4
Low 5 (23.8) 16 (76.2) Ref 0.001*
High 15 (78.9) 4 (21.1) 12 (2.7–53.33)
OR: Odds ratio, CI: Confidence interval, Ref: Reference. aSimple regression logistic test. *p < 0.05, means 
significant or statistically significant
Multivariate analysis of association of 
PD-L1 and CXCR4 immunoexpression with pelvic 
lymph node metastasis in cervical squamous cell 
carcinoma
The results of multivariate analysis show that 
all p values of all variables were less than 0.05 (p < 
0.05), showed PD-L1 and CXCR4 immunoexpression 
associated with pelvic lymph node metastasis in 
cervical SCC simultaneously. The variable that 
simultaneously had most influence on pelvic lymph 
node metastasis was CXCR4 immunoexpression (OR: 
13.797), then PD-L1 immunoexpression (OR: 10.042) 
(Table 5).
Table 5: Multivariate analysis of association of PD-L1 and 
CXCR4 immunoexpression with pelvic lymph node metastasis 
in cervical squamous cell carcinoma
Variable Coefficient p valuea OR OR CI 95%
Lower Upper
PD-L1 2.307 0.016* 10.042 1.548 65.151
CXCR4
Constant
2.624
−2.719
0.003* 13.797 2.376 80.102
OR: Odds ratio, CI: Confidence interval. aMultivariate analysis with multiple logistic regression. The 
independent variable included in this logistic regression is the independent variable which in the simple 
regression logistic test has p < 0.25. *p < 0.05, means significant or statistically significant.
Discussion
There are various studies analyzing the 
association of PD-L1 or CXCR4 immunoexpression 
with pelvic lymph node metastasis in cervical SCC, but 
in this study, we analyzed the association of both PD-L1 
and CXCR4 immunoexpression. We demonstrated 
that PD-L1 and CXCR4 immunoexpression were 
significantly higher in patients with cervical SCC 
displaying pelvic lymph node metastasis. The stepwise 
logistic regression analysis revealed that both PD-L1 
and CXCR4 immunoexpression influenced pelvic 
lymph node metastasis simultaneously. This result 
indicates that both PD-L1 and CXCR4 expression are 
upregulated in cervical SCC metastasize to pelvic lymph 
node cases and may contribute to the pelvic lymph 
node metastasis occurring in cervical SCC. The result 
of this study is consistent with the study performed by 
Meng et al. [27] that describe a significant correlation 
of PD-L1 overexpression with lymph node metastasis 
in cervical cancer. Similarly, the result of this study was 
also observed in the study performed by Dai et al. [29] 
and Kodama et al. [30] that describe a significant 
correlation of CXCR4 overexpression with lymph node 
metastasis in cervical cancer.
In many cancer, including cervical SCC, 
PD-L1, and CXCR4, upregulation is caused by intrinsic 
and extrinsic factors, such as genomic alterations and 
hypoxia [13], [32]. PD-L1 upregulation will induce T 
cell anergy, functional exhaustion, and apoptosis; 
increase inhibitory cytokines secretion (such as IL-10 
and TGF-β); and favor the conversion of T cells into 
Tregs which creates a local immunosuppressive 
condition in tumor microenvironment that inhibits 
anti-tumor immune response, results in immune 
evasion [20], [33]. Meanwhile, CXCR4 upregulation 
will activate pathways of the MEK/ERK, STAT3, and 
P13K/AKT which activates intracellular signals that 
play role in proliferation, survival, migration, and 
chemotaxis. In addition, PD-L1 upregulation will also 
cause the same pathways activation of the MEK/
ERK, STAT3, and P13K/AKT that cause CXCR4 
overexpression [13], [34]. This theory supports our 
result that PD-L1 and CXCR4 immunoexpression 
influenced pelvic lymph node metastasis in cervical 
SCC simultaneously.
This study showed that the risk of 
cervical SCC patients with high PD-L1 and CXR4 
immunoexpression for sustaining pelvic lymph node 
metastasis was 8.5 and 12 times higher than patients 
with low PD-L1 and CXCR4 immunoexpression, 
respectively. Interestingly, the risk of cervical 
SCC patients with both high PD-L1 and CXCR4 
immunoexpression for sustaining pelvic lymph node 
metastasis was increased to 10.042 and 13.797 times 
higher, respectively. The variable that simultaneously 
had most influence on pelvic lymph node metastasis 
was CXCR4 immunoexpression (OR: 13.797), then 
PD-L1 immunoexpression (OR: 10.042)
We need similar studies for the association 
of PD-L1 and CXCR4 immunoexpression with pelvic 
lymph node metastasis in cervical SCC to elucidate 
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more about mechanism of PD-L1 and CXCR4 affect 
pelvic lymph node metastasis simultaneously.
Conclusion
Our study showed that high immunoexpression 
of PD-L1 and CXCR4 in cervical SCC showed significant 
association with pelvic lymph node metastasis. It could 
be concluded that the higher PD-L1 and CXCR4 
immunoexpression showed the higher ability of tumor 
cells to metastasize to the pelvic lymph node. The 
results of this study should be considered to perform 
routine PD-L1 and CXCR4 immunoexpression of 
cervical SCC biopsy samples to predict pelvic lymph 
node metastasis in cervical SCC.
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